AAS
DFTX

Avantax Advisory Services’s Definium Therapeutics DFTX Stock Holding History

Avantax Advisory Services’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		$72.3K Sell
11,138
-459
-4% -$3.02K ﹤0.01% 2308
2025
Q1 		$67.8K Buy
11,597
+418
+4% +$2.99K ﹤0.01% 2186
2024
Q4 		$77.8K Buy
+11,179
New +$76.9K ﹤0.01% 2134

Other funds holding DFTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Avantax Advisory Services's DFTX Position: Q2 2025 in Review

Avantax Advisory Services reduced its Definium Therapeutics (DFTX) stake by 4% in Q2 2025, selling an estimated $3.02K and leaving 11,138 shares worth $72.3K. The position accounts for ﹤0.01% of the portfolio, ranked #2308.

Avantax Advisory Services first reported a position in DFTX in Q4 2024 and has held it in 3 quarters since. The position peaked at $77.8K in Q4 2024. 181 funds tracked by Wall St. Rank hold DFTX as of Q2 2025.

  • Avantax Advisory Services held 11,138 shares of Definium Therapeutics worth $72.3K as of Q2 2025.
  • Avantax Advisory Services sold 459 Definium Therapeutics shares in Q2 2025, an estimated $3.02K.
  • Definium Therapeutics made up ﹤0.01% of Avantax Advisory Services's portfolio in Q2 2025, its #2308 holding.
  • Avantax Advisory Services first reported a position in Definium Therapeutics in Q4 2024 and has held it in 3 quarters since.
  • Avantax Advisory Services's Definium Therapeutics position peaked at $77.8K in Q4 2024.
  • 181 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2025.

Based on Avantax Advisory Services's 13F filing for Q2 2025, filed 8 Aug 2025.